Rep. Maria Elvira Salazar Sells Biogen Inc. (NASDAQ:BIIB) Stock

Representative Maria Elvira Salazar (Republican-Florida) recently sold shares of Biogen Inc. (NASDAQ:BIIB). In a filing disclosed on July 07th, the Representative disclosed that they had sold between $15,001 and $50,000 in Biogen stock on June 2nd. The trade occurred in the Representative’s “UBS BROKERAGE ACCOUNT” account.

Representative Maria Elvira Salazar also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Voyager Technologies (NYSE:VOYG) on 6/15/2026.
• Sold $1,001 – $15,000 in shares of UnitedHealth Group (NYSE:UNH) on 6/4/2026.
• Purchased $15,001 – $50,000 in shares of Brookfield Renewable Partners (NYSE:BEP) on 6/4/2026.
• Purchased $1,001 – $15,000 in shares of Brookfield Renewable Partners (NYSE:BEP) on 6/4/2026.
• Purchased $1,001 – $15,000 in shares of Brookfield Renewable Partners (NYSE:BEP) on 6/3/2026.
• Purchased $1,001 – $15,000 in shares of Brookfield Renewable Partners (NYSE:BEP) on 6/2/2026.
• Purchased $15,001 – $50,000 in shares of Salesforce (NYSE:CRM) on 6/2/2026.
• Purchased $1,001 – $15,000 in shares of Brookfield Renewable Partners (NYSE:BEP) on 5/29/2026.
• Purchased $15,001 – $50,000 in shares of International Business Machines (NYSE:IBM) on 5/21/2026.
• Purchased $15,001 – $50,000 in shares of Datadog (NASDAQ:DDOG) on 5/19/2026.

Biogen Stock Down 2.6%

BIIB stock opened at $200.36 on Thursday. The company has a 50 day moving average of $197.84 and a two-hundred day moving average of $187.82. The company has a market cap of $29.58 billion, a price-to-earnings ratio of 21.50 and a beta of 0.16. Biogen Inc. has a 12-month low of $121.05 and a 12-month high of $219.72. The company has a quick ratio of 2.41, a current ratio of 3.06 and a debt-to-equity ratio of 0.34.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 EPS for the quarter, beating the consensus estimate of $2.95 by $0.62. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The business had revenue of $2.48 billion for the quarter, compared to analysts’ expectations of $2.29 billion. During the same period in the previous year, the company posted $3.02 EPS. Biogen’s revenue was up 1.9% on a year-over-year basis. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. On average, equities analysts anticipate that Biogen Inc. will post 13.95 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. Needham & Company LLC upped their target price on Biogen from $255.00 to $256.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. JPMorgan Chase & Co. boosted their price target on Biogen from $175.00 to $185.00 and gave the company a “neutral” rating in a research note on Thursday, April 23rd. Zacks Research downgraded Biogen from a “hold” rating to a “strong sell” rating in a report on Monday, June 29th. Piper Sandler reiterated an “overweight” rating and issued a $225.00 target price (up from $214.00) on shares of Biogen in a research note on Friday, May 15th. Finally, Citigroup boosted their target price on shares of Biogen from $190.00 to $200.00 and gave the stock a “neutral” rating in a research report on Friday, May 1st. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, twelve have issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, Biogen presently has an average rating of “Moderate Buy” and an average target price of $218.15.

Institutional Trading of Biogen

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Norges Bank bought a new position in Biogen during the fourth quarter valued at about $464,408,000. Boston Partners acquired a new position in shares of Biogen in the 4th quarter worth approximately $302,815,000. Fred Alger Management LLC boosted its stake in Biogen by 39,074.8% in the fourth quarter. Fred Alger Management LLC now owns 798,774 shares of the biotechnology company’s stock worth $140,576,000 after purchasing an additional 796,735 shares in the last quarter. Employees Provident Fund Board bought a new stake in Biogen during the 4th quarter worth about $123,931,000. Finally, Orion Porfolio Solutions LLC increased its holdings in shares of Biogen by 6,828.4% in the second quarter. Orion Porfolio Solutions LLC now owns 517,275 shares of the biotechnology company’s stock valued at $64,965,000 after purchasing an additional 509,809 shares in the last quarter. 87.93% of the stock is currently owned by institutional investors and hedge funds.

About Representative Salazar

Maria Elvira Salazar (Republican Party) is a member of the U.S. House, representing Florida’s 27th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027.

Salazar (Republican Party) ran for re-election to the U.S. House to represent Florida’s 27th Congressional District. She won in the general election on November 5, 2024.

Maria Elvira Salazar was born in Miami, Florida, and lives in Coral Gables, Florida. Salazar earned an undergraduate degree from the University of Miami in 1983 and a graduate degree from Harvard University in 1995. Her career experience includes working as a television journalist, reporter, and news anchor.

Biogen Company Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.